Pacira BioSciences Enters Into Agreement With LG Chem To Expand Access To Opioid-Sparing Postsurgical Pain Control For Patients In Select Asian-Pacific Markets
Benzinga Newsdesk 10 months ago
News
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
-- LG Chem becomes exclusive distributor of EXPAREL -- – Partnership expands patient access to opioid-sparing pain control and advances 5x30 strategy–BRISBANE, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pacira
-- LG Chem becomes exclusive distributor of EXPAREL --
– Partnership expands patient access to opioid-sparing pain control and advances 5x30 strategy–
BRISBANE, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced it has entered into an agreement with LG Chem designed to expand access to opioid-sparing postsurgical pain control for patients in select Asian-Pacific markets. Through this partnership, LG Chem has the exclusive rights to commercialize EXPAREL® (bupivacaine liposome injectable suspension), Pacira's long-acting, local analgesic for postsurgical pain management in the region.